Main implications related to the switch to BRCA1/2 tumor testing in ovarian cancer patients: a proposal of a consensus

BACKGROUND: Since the approval of the first poly (adenosine diphosphate [ADP]) ribose polymerase inhibitor (PARPi; olaparib [Lynparza™]) for platinum-sensitive relapsed high grade ovarian cancer, with either germline or somatic BRCA1/2 deleterious variants, the strategies for BRCA1/2 are dynamically...

Descripción completa

Detalles Bibliográficos
Autores principales: Capoluongo, Ettore, Scambia, Giovanni, Nabholtz, Jean-Marc
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2018
Materias:
Research Perspective
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5929401/
https://www.ncbi.nlm.nih.gov/pubmed/29731958
http://dx.doi.org/10.18632/oncotarget.24728

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5929401/
https://www.ncbi.nlm.nih.gov/pubmed/29731958
http://dx.doi.org/10.18632/oncotarget.24728

Ejemplares similares